All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Biomarker Driven Cancer Therapeutics: Existing Tools and Remaining Gaps

DOI: 10.4236/oalib.1106556, PP. 1-10

Subject Areas: Oncology

Keywords: Cancer Biomarkers, Breast Cancer, Lung Cancer

Full-Text   Cite this paper   Add to My Lib

Abstract

Advancements in technology such as proteomics, genomics have led to the concept of personalized medicine wherein the integration of biomarkers into clinic directs cancer therapeutics. Traditional staging has a stochastic element which can only predict the outcome without actual consideration of intrapatient heterogeneity. In this review, we will look at the biomarkers that prove to be valuable tools for the personalization of cancer therapeutics among lung and breast cancer patients.

Cite this paper

Senga, S. S. and Arakelyan, J. (2020). Biomarker Driven Cancer Therapeutics: Existing Tools and Remaining Gaps. Open Access Library Journal, 7, e6556. doi: http://dx.doi.org/10.4236/oalib.1106556.

References

[1]  Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]  Vaught, D., Stanford, J., Young, C., Hicks, D., Wheeler, F., Rinehart, C., Sanchez, V., Koland, J., Muller, W., Arteaga, C. and Cook, R. (2012) HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation. Cancer Research, 72, 2672-2682. https://doi.org/10.1158/0008-5472.CAN-11-3594
[3]  Hanna, W., Slodkowska, E., Lu, F., Nafisi, H. and Nofech-Mozes, S. (2017) Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations. Journal of Clinical Oncology, 35, 3039-3045. https://doi.org/10.1200/JCO.2016.70.5319
[4]  Slamon, D., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J. and Norton, L. (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 344, 783-792. https://doi.org/10.1056/NEJM200103153441101
[5]  Allred, D. (2010) Issues and Updates: Evaluating Estrogen Receptor-α, Progesterone Receptor, and HER2 in Breast Cancer. Modern Pathology, 23, S52-S59. https://doi.org/10.1038/modpathol.2010.55
[6]  Achinger-Kawecka, J., Valdes-Mora, F., Luu, P., Giles, K., Caldon, C., Qu, W., Nair, S., Soto, S., Locke, W., Yeo-Teh, N., Gould, C., Du, Q., Smith, G., Ramos, I., Fernandez, K., Hoon, D., Gee, J., Stirzaker, C. and Clark, S. (2020) Epigenetic Reprogramming at Estrogen-Receptor Binding Sites Alters 3D Chromatin Landscape in Endocrine-Resistant Breast Cancer. Nature Communications, 11, Article No. 320. https://doi.org/10.1038/s41467-019-14098-x
[7]  Mohammed, H., Russell, I., Stark, R., Rueda, O., Hickey, T., Tarulli, G., Serandour, A., Birrell, S., Bruna, A., Saadi, A., Menon, S., Hadfield, J., Pugh, M., Raj, G., Brown, G., D’Santos, C., Robinson, J., Silva, G., Launchbury, R., Perou, C., Stingl, J., Caldas, C., Tilley, W. and Carroll, J. (2015) Progesterone Receptor Modulates ERα Action in Breast Cancer. Nature, 523, 313-317. https://doi.org/10.1038/nature14583
[8]  Campbell, E., Tesson, M., Doogan, F., Mohammed, Z., Mallon, E. and Edwards, J. (2016) The Combined Endocrine Receptor in Breast Cancer, a Novel Approach to Traditional Hormone Receptor Interpretation and a Better Discriminator of Outcome than ER and PR Alone. British Journal of Cancer, 115, 967-973. https://doi.org/10.1038/bjc.2016.206
[9]  Yeo, B., Zabaglo, L., Hills, M., Dodson, A., Smith, I. and Dowsett, M. (2015) Clinical Utility of the IHC4 C Score in Oestrogen Receptor-Positive Early Breast Cancer: A Prospective Decision Impact Study. British Journal of Cancer, 113, 390-395. https://doi.org/10.1038/bjc.2015.222
[10]  Krop, I., Ismaila, N., Andre, F., Bast, R., Barlow, W., Collyar, D., Hammond, M., Kuderer, N., Liu, M., Mennel, R., Van Poznak, C., Wolff, A. and Stearns, V. (2017) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 35, 2838-2847. https://doi.org/10.1200/JCO.2017.74.0472
[11]  Harris, L., Ismaila, N., McShane, L., Andre, F., Collyar, D., Gonzalez-Angulo, A., Hammond, E., Kuderer, N., Liu, M., Mennel, R., Van Poznak, C., Bast, R. and Hayes, D. (2016) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 34, 1134-1150. https://doi.org/10.1200/JCO.2015.65.2289
[12]  Martín, M., González-Rivera, M., Morales, S., de la Haba-Rodriguez, J., González-Cortijo, L., Manso, L., Albanell, J., González-Martín, A., González, S., Arcusa, A., de la Cruz-Merino, L., Rojo, F., Vidal, M., Galván, P., Aguirre, E., Morales, C., Ferree, S., Pompilio, K., Casas, M., Caballero, R., Goicoechea, U., Carrasco, E., Michalopoulos, S., Hornberger, J. and Prat, A. (2015) Prospective Study of the Impact of the Prosigna Assay on Adjuvant Clinical Decision-Making in Unselected Patients with Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor Negative, Node Negative Early-Stage Breast Cancer. Current Medical Research and Opinion, 31, 1129-1137. https://doi.org/10.1185/03007995.2015.1037730
[13]  Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M., Petry, C., Weber, K., Kronenwett, R., Brase, J. and Gnant, M. (2013) EndoPredict Improves the Prognostic Classification Derived from Common Clinical Guidelines in ER-Positive, HER2-Negative Early Breast Cancer. Annals of Oncology, 24, 640-647. https://doi.org/10.1093/annonc/mds334
[14]  Siegel, R., Miller, K. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. https://doi.org/10.3322/caac.21442
[15]  .Pan, J., Zhou, C., Zhao, X., He, J., Tian, H., Shen, W., Han, Y., Chen, J., Fang, S., Meng, X., Jin, X. and Gong, Z. (2018) A Two-miRNA Signature (miR-33a-5p and miR-128-3p) in Whole Blood as Potential Biomarker for Early Diagnosis of Lung Cancer. Scientific Reports, 8, Article No. 16699. https://doi.org/10.1038/s41598-018-35139-3
[16]  Yang, L., Yang, J., Li, J., Shen, X., Le, Y., Zhou, C., Wang, S., Zhang, S., Xu, D. and Gong, Z. (2015) MircoRNA-33a Inhibits Epithelial-to-Mesenchymal Transition and Metastasis and Could Be a Prognostic Marker in Non-Small Cell Lung Cancer. Scientific Reports, 5, Article No. 13677. https://doi.org/10.1038/srep13677
[17]  Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., Wang, Q., Bai,H., Han, J., Tian, Y., Lu, J., Xu, T., Zhao, X., Wang, G., Cao, X., Li, F., Wang, D., Chen, Y., Bai, Y., Zhao, J., Zhao, Z., Zhang, Y., Xiong, L., He, J., Gao, S. and Wang, J. (2019) Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients with Non-Small Cell Lung Cancer with Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncology, 5, 696. https://doi.org/10.1001/jamaoncol.2018.7098
[18]  Garon, E., Hellmann, M., Rizvi, N., Carcereny, E., Leighl, N., Ahn, M., Eder, J., Balmanoukian, A., Aggarwal, C., Horn, L., Patnaik, A., Gubens, M., Ramalingam, S., Felip, E., Goldman, J., Scalzo, C., Jensen, E., Kush, D. and Hui, R. (2019) Five-Year Overall Survival for Patients with Advanced Non-Small-Cell Lung Cancer Treated with Pembrolizumab: Results from the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 37, 2518-2527. https://doi.org/10.1200/JCO.19.00934
[19]  Inamura, K. (2018) Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers, 10, 72. https://doi.org/10.3390/cancers10030072
[20]  Solomon, B., Mok, T., Kim, D., Wu, Y., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K., Tursi, J. and Blackhall, F. (2014) First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 371, 2167-2177. https://doi.org/10.1056/NEJMoa1408440
[21]  Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A., Léna, H., Monnet, I., Rothschild, S., Cappuzzo, F., Besse, B., Thiberville, L., Rouvière, D., Dziadziuszko, R., Smit, E., Wolf, J., Spirig, C., Pecuchet, N., Leenders, F., Heuckmann, J., Diebold, J., Milia, J., Thomas, R. and Gautschi, O. (2015) Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results from the EUROS1 Cohort. Journal of Clinical Oncology, 33, 992-999. https://doi.org/10.1200/JCO.2014.58.3302
[22]  Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y., Okumura, S., Nakagawa, K. and Ishikawa, Y. (2008) ATP Citrate Lyase: Activation and Therapeutic Implications in Non-Small Cell Lung Cancer. Cancer Research, 68, 8547-8554. https://doi.org/10.1158/0008-5472.CAN-08-1235
[23]  Chen, Y., Li, K., Gong, D., Zhang, J., Li, Q., Zhao, G. and Lin, P. (2020) ACLY: A Biomarker of Recurrence in Breast Cancer. Pathology—Research and Practice, 216, Article ID: 153076. https://doi.org/10.1016/j.prp.2020.153076
[24]  Sims, A., Howell, A., Howell, S. and Clarke, R. (2007) Origins of Breast Cancer Subtypes and Therapeutic Implications. Nature Clinical Practice Oncology, 4, 516-525. https://doi.org/10.1038/ncponc0908
[25]  Hanash, S., Ostrin, E. and Fahrmann, J. (2018) Blood Based Biomarkers beyond Genomics for Lung Cancer Screening. Translational Lung Cancer Research, 7, 327-335. https://doi.org/10.21037/tlcr.2018.05.13
[26]  Melosky, B., Blais, N., Cheema, P., Couture, C., Juergens, R., Kamel-Reid, S., Tsao, M., Wheatley-Price, P., Xu, Z. and Ionescu, D. (2018) Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology, 25, 73. https://doi.org/10.3747/co.25.3867
[27]  Lin, Y., Wu, J., Tseng, C., Chen, H. and Wang, L. (2018) Gjb4 Serves as a Novel Biomarker for Lung Cancer and Promotes Metastasis and Chemoresistance via Src Activation. Oncogene, 38, 822-837. https://doi.org/10.1038/s41388-018-0471-1

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal